Works Cited

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Available at https://www.cdc.gov/diabetes/data/statistics-report/index.html. Last accessed October 25, 2022.

2. Centers for Disease Control and Prevention. Division of Diabetes Translation At a Glance. Available at https://www.cdc.gov/chronicdisease/resources/publications/aag/diabetes.htm. Last accessed October 25, 2022.

3. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff (Millwood). 2010;29(2):297-303.

4. American Diabetes Association. The Cost of Diabetes. Available at https://diabetes.org/about-us/statistics/cost-diabetes. Last accessed October 25, 2022.

5. Davis J, Fischl AH, Beck J, et al. 2022 National standards for diabetes self-management education and support. Diabetes Care. 2022;45:484-494.

6. American Diabetes Association. Standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Suppl 1):S1-S259.

7. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.

8. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2002;25(Suppl 1):S28-S32.

9. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Circulation. 2009;119(2):351-357.

10. American Diabetes Association. Statistics About Diabetes. Available at https://diabetes.org/about-us/statistics/about-diabetes. Last accessed October 25, 2022.

11. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884-1890.

12. Fradkin J, Rodgers GP. The economic imperative to conquer diabetes. Diabetes Care. 2008;31(3):624-625.

13. National Indian Council on Aging, Inc. Diabetes Still Highest Among AI/AN. Available at https://www.nicoa.org/diabetes-still-highest-among-ai-an/#. Last accessed October 25, 2022.

14. Roberts H, Jiles R, Mokdad A, Beckles G. Rios-Burrows N. Trend analysis of diagnosed diabetes prevalence among American Indian/Alaska Native young adults—United States, 1994–2007. Ethnicity Disease. 2009;19:276-279.

15. U.S. Department of Health and Human Services, Office of Minority Health. Diabetes and African Americans. Available at https://www.minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=18. Last accessed October 25, 2022.

16. U.S. Department of Health and Human Services, Office of Minority Health. Diabetes and Hispanic Americans. Available at https://www.minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=63. Last accessed October 25, 2022.

17. U.S. Department of Health and Human Services, Office of Minority Health. Diabetes and Asian and Pacific Islanders. Available at https://www.minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=48. Last accessed October 25, 2022.

18. LexiComp Online. Available at https://online.lexi.com/lco/action/login. Last accessed October 25, 2022.

19. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S127-S138.

20. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.

21. Centers for Disease Control and Prevention About Prediabetes and Type 2 Diabetes. Available at https://www.cdc.gov/diabetes/prevention/about-prediabetes.html. Last accessed October 25, 2022.

22. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med. 2002;346(6):393-403.

23. Centers for Disease Control and Prevention. CDC-Recognized Lifestyle Change Program. Why Participate? Available at https://www.cdc.gov/diabetes/prevention/why-participate.html. Last accessed October 25, 2022.

24. American Diabetes Association. Children and adolescents: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S208-S231.

25. National Institute of Diabetes and Digestive and Kidney Diseases. Pancreatic Islet Transplantation. Available at https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments/pancreatic-islet-transplantation. Last accessed October 25, 2022.

26. American Diabetes Association. Gestational Diabetes. Available at https://www.diabetes.org/diabetes/gestational-diabetes. Last accessed October 25, 2022.

27. Centers for Disease Control and Prevention. Diabetes Risk Factors: Gestational Diabetes. Available at https://www.cdc.gov/diabetes/basics/risk-factors.html. Last accessed October 25, 2022.

28. Frazzitta M. Gestational Diabetes: Diagnosis to Delivery. San Diego, CA: PESI Healthcare; 2013.

29. Noctor E, Crowe C, Carmody LA, et al. Abnormal glucose tolerance post-gestational diabetes mellitus as defined by the International Association of Diabetes and Pregnancy Study Groups criteria. Eur J Endocrinol. 2016;175:287-297.

30. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25:1862-1868.

31. American Diabetes Association. Gestational Diabetes: Treatment and Perspective. Available at https://www.diabetes.org/diabetes/gestational-diabetes/how-to-treat-gestational-diabetes. Last accessed October 25, 2022.

32. American Diabetes Association. DKA (Ketoacidosis) and Ketones. Available at https://www.diabetes.org/diabetes/complications/dka-ketoacidosis-ketones. Last accessed October 25, 2022.

33. Centers for Disease Control and Prevention. Diabetic Ketoacidosis. Available at https://www.cdc.gov/diabetes/basics/diabetic-ketoacidosis.html#. Last accessed October 25, 2022.

34. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343.

35. Davidson MB, Scwartz S. Hyperglycemia. In: Franz MJ (ed). A Core Curriculum for Diabetes Education: Diabetes and Complications. 5th ed. Chicago, IL: American Association of Diabetes Educators; 2003.

36. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928.

37. Centers for Disease Control and Prevention. Prevent Diabetes Complications. Available at https://www.cdc.gov/diabetes/managing/problems.html. Last accessed October 25, 2022.

38. National Institute of Diabetes and Digestive and Kidney Diseases. Blood Glucose Control Studies for Type 1 Diabetes: DCCT and EDIC. Available at https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/blood-glucose-control-studies-type-1-diabetes-dcct-edic. Last accessed October 25, 2022.

39. Reutens AT, Atkins RC. Epidemiology of diabetic nephropathy. Contrib Nephrol. 2011;170:1-7.

40. Sharma AM, Weir MR. The role of angiotensin receptor blockers in diabetic nephropathy. Postgrad Med. 2011;123(3):109-121.

41. Mayo Clinic. Diabetic Neuropathy. Available at https://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/symptoms-causes/syc-20371580#. Last accessed October 25, 2022.

42. American Heart Association. Cardiovascular Disease and Diabetes. Available at https://www.heart.org/en/health-topics/diabetes/diabetes-complications-and-risks/cardiovascular-disease--diabetes. Last accessed October 25, 2022.

43. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-125.

44. Polonsky WH. Diabetes Burnout: What to Do When You Can't Take It Anymore. Alexandria, VA: American Diabetes Association; 1999.

45. Rubin RR, Napora JP. Psychosocial assessment. In: Franz MJ (ed). A Core Curriculum for Diabetes Education: Diabetes and Complications. 5th ed. Chicago, IL: American Association of Diabetes Educators; 2003.

46. Prochaska JO, DiClemente CC. Common processes of self-change in smoking, weight control, and psychological distress. In: Shiffman S (ed). Coping and Substance Abuse: A Conceptual Framework. New York, NY: Academic Press; 1985: 345-363.

47. Dart MA. Motivational Interviewing in Nursing Practice. Sudbury, MA: Jones and Bartlett; 2011.

48. Duncan I, Birkmeyer C, Coughlin S, Li QE, Sherr D, Boren S. Assessing the value of diabetes education. Diabetes Educ. 2009;35(5):752-760.

49. U.S. Department of health and Human Services. Healthy People 2030. Available at https://health.gov/healthypeople. Last accessed October 25, 2022.

50. Centers for Disease Control and Prevention. Diabetes Self-Management Education and Support. Available at https://www.cdc.gov/diabetes/library/reports/reportcard/diabetes-self-management-education-support.html. Last accessed October 25, 2022.

51. International Diabetes Federation. Self-Monitoring of Blood Glucose in Non-Insulin-Treated Type 2 Diabetes. Available at https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/85:self-monitoring-of-blood-glucose-in-non-insulin-treated-type-2-diabetes.html. Last accessed October 25, 2022.

52. Martin S, Schneider B, Heinnemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia. 2006;49(2):271-278.

53. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006;295(14):1688-1697.

54. Malanda UL, Welschen LMC, Riphagen II, Dekker JM. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012;(1):CD005060.

55. DTS Blood Glucose Monitoring System Surveillance Program. Available at https://www.diabetestechnology.org/surveillance. Last accessed October 25, 2022.

56. American Diabetes Association. The Big Picture: Checking Your Blood Glucose. Available at https://diabetes.org/healthy-living/medication-treatments/blood-glucose-testing-and-control/checking-your-blood-sugar. Last accessed October 25, 2022.

57. Cox DJ, Taylor AG, Moncrief M, et al. Continuous glucose monitoring in the self-management of type 2 diabetes: a paradigm shift. Diabetes Care. 2016;39(5):e71-e73.

58. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Pediatric Use of Dexcom's G4 Platinum Continuous Glucose Monitoring System. Available at https://wayback.archive-it.org/7993/20170112222919/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm384495.htm. Last accessed October 25, 2022.

59. U.S. Food and Drug Administration. Press Release: FDA Approves First Continuous Glucose Monitoring System for Adults Not Requiring Blood Sample Calibration. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-continuous-glucose-monitoring-system-adults-not-requiring-blood-sample. Last accessed October 25, 2022.

60. Abbott. Abbott's Freestyle Libre 2 ICGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards. Available at https://abbott.mediaroom.com/2020-06-15-Abbotts-FreeStyle-R-Libre-2-iCGM-Cleared-in-U-S-for-Adults-and-Children-with-Diabetes-Achieving-Highest-Level-of-Accuracy-and-Performance-Standards. Last accessed October 25, 2022.

61. Black E. Abbott Has a New Glucose Monitor for Diabetics – It's So Small I Forgot I Was Wearing It. Available at https://www.cnbc.com/2022/10/14/review-abbott-freestyle-libre-3-cgm-for-diabetics-.html. Last accessed October 25, 2022.

62. Tucker ME. FDA Approves New 'Smart' Continuous Glucose Monitor for Diabetes. Available at https://www.medscape.com/viewarticle/893851. Last accessed October 25, 2022.

63. U.S. Food and Drug Administration. Press Release: FDA Authorizes First Fully Interoperable Continuous Glucose Monitoring System, Streamlines Review Pathway for Similar Devices. Available at https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review. Last accessed October 25, 2022.

64. Doyle-Delgado K, Chamberlain JJ. Use of diabetes-related applications and digital health tools by people with diabetes and their health care providers. Clin Diabetes. 2020;38(5):449-461.

65. American Diabetes Association. A1C and eAG. Available at https://www.diabetes.org/diabetes/a1c-test-meaning/a1c-and-eag. Last accessed October 25, 2022.

66. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1345-1422.

67. Pan A, Lin X, Hemler E, Hu FB. Diet and cardiovascular disease: advances and challenges in population-based studies. Cell Metab. 2018;27(3):489-496.

68. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014;383(9933):1999-2007.

69. Joslin Diabetes. What Impacts Glucose Levels in Your Diet. Available at https://www.joslin.org/patient-care/diabetes-education/diabetes-learning-center/what-impacts-glucose-levels-your-diet. Last accessed October 25, 2022.

70. American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31(Suppl 1):S61-S78.

71. Morris SF, Wylie-Rosett J. Medical nutrition therapy: a key to diabetes management and prevention. Clinical Diabetes. 2010;28(1):12-18.

72. Franz MJ, Powers MA, Leontos C, et al. The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults.J Am Diet Assoc. 2010;110(12):1852-1889.

73. DGA. Dietary Guidelines for Americans, 2020-2025 and Online Materials. Available at https://www.dietaryguidelines.gov/resources/2020-2025-dietary-guidelines-online-materials. Last accessed October 25, 2022.

74. U.S. Department of Agriculture MyPlate. Learn How to Eat Healthy With MyPlate. Available at https://www.myplate.gov/. Last accessed October 25, 2022.

75. American Diabetes Association. My Food Advisor: Create Your Plate. Available at http://hmassoc.org/wp-content/uploads/Create-Your-Plate-2.pdf. Last accessed October 25, 2022.

76. Evert AB, Boucher JL, Cypress M, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2013;36(11):3821-3842.

77. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42(5):731-754.

78. American Diabetes Association. Carb Counting and Diabetes. Available at https://diabetes.org/healthy-living/recipes-nutrition/understanding-carbs/carb-counting-and-diabetes. Last accessed October 25, 2022.

79. Mayo Clinic. Tips for Prediabetes and Diabetes Meal Planning. Available at https://newsnetwork.mayoclinic.org/discussion/tips-for-prediabetes-and-diabetes-meal-planning/. Last accessed October 25, 2022.

80. Pedersen SD, Kang J, Kline GA. Portion control plate for weight loss in obese patients with type 2 diabetes mellitus: a controlled clinical trial. Arch Intern Med. 2007;167(12):1277-1283.

81. Rizor H, Smith M, Thomas K, Harker J, Rich M. Have you tried the Idaho plate method? DCE Newsflash. 1996;17:18-20.

82. Raidl M, Spain K, Lanting R, et al. The healthy diabetes plate. Prev Chronic Dis. 2007;4(1).

83. Idaho Plate Method. Available at http://www.platemethod.com. Last accessed October 25, 2022.

84. University of Idaho. Healthy Diabetes Plate, 2nd Edition. Available at https://marketplace.uidaho.edu/C20272_ustores/web/product_detail.jsp?PRODUCTID=2675. Last accessed October 25, 2022.

85. Seagle HM, Strain GW, Makris A, Reeves RS, American Dietetic Association. Position of the American Dietetic Association: weight management. J Am Diet Assoc. 2009;109(2):330-346.

86. American Diabetes Association. Non-Starchy Vegetables. Available at https://www.diabetes.org/nutrition/healthy-food-choices-made-easy/non-starchy-vegetables. Last accessed October 25, 2022.

87. American Diabetes Association. What Are My Options? Available at https://www.diabetes.org/diabetes/medication-management/oral-medication/what-are-my-options. Last accessed October 25, 2022.

88. Joslin Diabetes Center. Clinical Guideline for Pharmacological Management of Adults with Type 2 Diabetes. Available at https://joslin-prod.s3.amazonaws.com/www.joslin.org/assets/2020-07/pharma-guideline-07-03-20_0.pdf. Last accessed October 25, 2022.

89. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.

90. GlaxoSmithKline. Highlights of Prescribing Information: Avandia. Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avandia/pdf/AVANDIA-PI-MG.PDF. Last accessed October 25, 2022.

91. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience. NEJM. 2013;369(14):1285-1287.

92. Tanne JH. FDA places "black box" warning on antidiabetes drugs. BMJ. 2007;334(7606):1237.

93. Comerford KC (ed). Nursing 2023 Drug Handbook. 43rd ed. Philadelphia, PA: Wolters Kluwer; 2023.

94. Daily Med. Available at https://dailymed.nlm.nih.gov/dailymed/index.cfm. Last accessed October 25, 2022.

95. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Tanzeum to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023843/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm. Last accessed October 25, 2022.

96. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Trulicity to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023822/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm. Last accessed October 25, 2022.

97. U.S. Food and Drug Administration. Press Release: FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes. Last accessed October 25, 2022.

98. U.S. Food and Drug Administration. Highlights of Prescribing Information. Rybelsus (semaglutide). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf. Last accessed October 25, 2022.

99. U.S. Food and Drug Administration. Archive: FDA Drug Safety Podcast. FDA Investigating Reports of Possible Increased Risk of Pancreatitis and Pre-Cancerous Findings of the Pancreas from Incretin Mimetic Drugs for Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170722185812/https://www.fda.gov/Drugs/DrugSafety/ucm343187.htm. Last accessed October 25, 2022.

100. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin 4) on glycemic control and weight over 30 weeks in sulfonylurea treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.

101. Campbell RK, Miller S. New therapeutic horizons: mapping the future of glycemic control with incretin-based therapies. Diabetes Educ. 2009;35(5):731-734, 738-740, 742-744.

102. Merck & Co. Medication Guide: Januvia. Available at https://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_mg.pdf. Last accessed October 25, 2022.

103. Bristol-Myers Squibb. Onglyza. Available at https://www.onglyza.com. Last accessed October 25, 2022.

104. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Three New Drug Treatments for Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023907/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm. Last accessed October 25, 2022.

105. DailyMed. SymlinPen. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff. Last accessed October 25, 2022.

106. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Invokana to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023858/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Last accessed October 25, 2022.

107. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Farxiga to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023850/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm. Last accessed October 25, 2022.

108. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Jardiance to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023827/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm. Last accessed October 25, 2022.

109. Pfizer. FDA Approves SGLT2 Inhibitor STEGLATRO (ertugliflozin) and Fixed-Dose Combination STEGLUJAN (ertugliflozin and sitagliptin) for Adults with Type 2 Diabetes. Available at https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_sglt2_inhibitor_steglatro_ertugliflozin_and_fixed_dose_combination_steglujan_ertugliflozin_and_sitagliptin_for_adults_with_type_2_diabetes. Last accessed October 25, 2022.

110. U.S. Food and Drug Administration. Archive: Safety Announcement. FDA Warns about Rare Occurrences of a Serious Infection of the Genital Area with SGLT2 Inhibitors for Diabetes. Available at https://wayback.archive-it.org/7993/20190207173939/https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm. Last accessed October 25, 2022.

111. Fonseca V. Oxford American Endocrinology Library: Improving Patient Care. New York, NY: Oxford University Press; 2009.

112. American Diabetes Association. Hypoglycemia (Low Blood Sugar). Available at https://www.diabetes.org/diabetes/medication-management/blood-glucose-testing-and-control/hypoglycemia. Last accessed October 25, 2022.

113. Gonder-Frederick LA. Hypoglycemia. In: Franz MJ (ed). A Core Curriculum for Diabetes Education: Diabetes and Complications. 5th ed. Chicago, IL: American Association of Diabetes Educators; 2003.

114. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Afrezza to Treat Diabetes. Available at https://wayback.archive-it.org/7993/20170112222845/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm. Last accessed October 25, 2022.

115. U.S. Food and Drug Administration. Highlights of Prescribing Information. Afrezza. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdf. Last accessed October 25, 2022.

116. American Diabetes Association. Insulin administration. Diabetes Care. 2003;26(Suppl 1):S121-S124.

117. American Diabetes Association. Insulin Storage and Syringe Safety. Available at https://www.diabetes.org/diabetes/medication-management/insulin-other-injectables/insulin-storage-and-syringe-safety. Last accessed October 25, 2022.

118. American Diabetes Association. Device Technology: Better Blood Glucose Meters and More. Available at https://www.diabetes.org/diabetes/device-technology. Last accessed October 25, 2022.

119. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves First Automated Insulin Delivery Device for Type 1 Diabetes. Available at https://wayback.archive-it.org/7993/20170111083713/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522974.htm. Last accessed October 52, 2022.

120. Medtronic. The MiniMed 770G System. Available at https://www.medtronicdiabetes.com/products/minimed-770g-insulin-pump-system. last accessed October 25, 2022.

121. American Diabetes Association. Continuous subcutaneous insulin infusion. Diabetes Care. 2004;27(Suppl 1):S110.

122. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and 2 diabetes: a position statement from the American Diabetes Association. Diabetes Care. 2016;39(11):2065-2079.

123. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1423-1434.

124. Mavros Y, Kay S, Anderberg KA, et al. Changes in insulin resistance and HbA1c are related to exercise-mediated changes in body composition in adults with type 2 diabetes: interim outcomes from the GREAT2DO trial. Diabetes Care. 2013;36(8):2372-2379.

125. Bronze MS. Diabetic Foot Infections. Available at https://emedicine.medscape.com/article/237378-overview. Last accessed October 25, 2022.

126. Bloomgarden ZT. The diabetic foot. Diabetes Care. 2008;31(2):372-376.

127. American Diabetes Association. Preventive foot care in diabetes. Diabetes Care. 2004;27(Suppl 1):S63-S64.

128. Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabet Med. 2014;31(7):764-772.

Evidence-Based Practice Recommendations Citations

1. Redmon B, Caccamo D, Flavin P, et al. Diagnosis and Management of Type 2 Diabetes Mellitus in Adults. Bloomington, MN: Institute for Clinical Systems Improvement; 2014. Available at https://www.icsi.org/wp-content/uploads/2019/02/Diabetes.pdf. Last accessed October 28, 2022.

2. Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Ann Intern Med. 2020;173(10):813-821. Available at https://www.acpjournals.org/doi/10.7326/M20-2470. Last accessed October 28, 2022.


Copyright © 2022 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.